Cartesian Therapeutics (RNAC) Non-Current Assets (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Non-Current Assets data on file, last reported at $166.4 million in Q1 2026.

• On a quarterly basis, Non-Current Assets fell 25.74% year-over-year to $166.4 million in Q1 2026; TTM through Mar 2026 was $784.4 million, a 12.02% decrease from a year earlier, with the FY2025 full-year figure at $167.1 million, down 23.47% from the prior year.
• Non-Current Assets for Q1 2026 stood at $166.4 million, roughly flat from $167.1 million in the prior quarter.
• Over the last five years, Non-Current Assets for RNAC reached as high as $226.2 million in Q3 2024 and fell as low as $15.5 million in Q2 2022.
• Historically, Non-Current Assets has averaged $130.7 million across 5 years, with a median of $167.1 million in 2025.
• Across the five-year window, Non-Current Assets soared 1299.2% in 2024 and fell 25.74% in 2026, its largest moves.
• Year by year, Non-Current Assets stood at $17.7 million in 2022, then surged by 1107.58% to $214.3 million in 2023, then climbed by 1.9% to $218.4 million in 2024, then declined by 23.47% to $167.1 million in 2025, then slipped by 0.47% to $166.4 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $166.4 million in Q1 2026, $167.1 million in Q4 2025, and $225.4 million in Q3 2025.